Therapeutic Apheresis in the Treatment of Hemolytic Uremic Syndrome in View of Pathophysiological Aspects

Therapeutic Apheresis and Dialysis

Volumn 15, Issue 1, 2011, Pages 10-19

  Bambauer, Rolf ^a   Latza, Reinhard ^b   Schiel, Ralf ^c  

^a Institute for Blood Purification   (Germany)

^b Laboratory of Medicine   (Germany)

^c Clinic for Metabolic Diseases   (Germany)

Author keywords

Hemolytic uremic syndrome; Immunoadsorption; Therapeutic apheresis; Toxin exposure

Indexed keywords

ACUTE KIDNEY FAILURE; APHERESIS; DISEASE COURSE; HEMOLYTIC UREMIC SYNDROME; INFECTION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

BLOOD COMPONENT REMOVAL; HEMOLYTIC-UREMIC SYNDROME; HUMANS;

EID: 79251548284     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2010.00903.x     Document Type: Review

References (110)

1. Viatel P, Chenas F, Dechelette E etal. Syndrome hémolytique et urémique de l'adulte traité avec succès par plasmaphérèses massives. J Urol Nephrol 1979;85:331-4.
2. Beattie TJ, Murphy AV, Willoughby MLN. Plasmapheresis in the haemolytic-uremic syndrome in children. Br Med J 1981;282:1667-70.
3. Parnes B, Dube VE, Simon NM etal. Adult hemolytic uremic syndrome successfully treated with plasma exchange. Plasma Ther Transfus Technol 1982;3:57-61.
4. Spencer CD, Crane FM, Kumar JR etal. Treatment of postpartum haemolytic uremic syndrome with plasma exchange. JAMA 1982;247:2808-10.
5. Bambauer R, Jutzler GA, Hartmann HG etal. Hemolytic uremic syndrome successfully treated with plasma exchange. In: Nosé Y, Malchesky PS, Smith JW etal., eds. Plasmapheresis: Therapeutic Applications and New Techniques. New York: Raven Press, 1983;379-86.
6. Gillor A, Roth B, Bulla M etal. Plasmapherese bei der Behandlung von Kindern mit hämolytisch-urämischem Syndrom. Nieren-Hochdruckkrankh 1986;15:118-24.
7. Mugo AJ. Plasmapheresis and antiplatelet agents in the treatment of the haemolytic uremic syndrome secondary to mitomycin. Am J Kidey Dis 1987;9:241-5.
8. Gasser C, Gautier E, Steck A etal. Hämolytisch-urämische Syndrome: Bilaterale Nierenrindennekrosen bei akuten erworbenen hämolytischen Anämien. Schweiz Med Wochenschr 1955;85:905-11.
9. Kaplan BS, Koornhof HJ. Haemolytic-uraemic syndrome: failure to demonstrate circulating endotoxin. Lancet 1969;II:1424-25.
10. Wehinher H, Sutor HA, Schindera F etal. Zur Therapie des hämolytisch-urämischen Syndroms. Dtsch Med Wschr 1974;99:840-5.
11. Zimmerhackl LB, Verwegen H, Gerber A etal. Das hämolytisch-urämische Syndrom. Deut Ärztebl 2002;99:A197-203.
12. Reppetto HA. Epidemic hemolytic-uremic syndrome in children. Kidney Int 1997;52:11708-19.
13. Karlsberg RP, Lacher JW, Bartechi CE. Adult hemolytic-uremic syndrome. Arch Intern Med 1977;137:1155-9.
14. Tsugawa Y, Hirata M, Nakashima A etal. A case report of adult hemolytic uremic syndrome. Nipp Jin Gak Shi 1987;29:97-100.
15. Brandt P, Jespersen J, Gregersen G. Post partum haemolytic-uremic syndrome treated with antithrombin-III. Nephron 1981;27:15-9.
16. Finkelstein FO, Kashgarian M, Hayslett JP. Clinical spectrum of postpartum renal failure. Am J Med 1974;57:649-54.
17. Tobon H. Malignant hypertension, uremia and hemolytic anemia in a patient on oral contraceptives. Am J Obstet Gynecol 1972;40:681-6.
18. Poschmann A, Fischer K. Hämolytisch-urämisches Syndrom. Med Klin 1974;69:1821-34.
19. Koch KM, Dippel J. Das hämolytisch-urämische Syndrom. Int Welt 1982;5:388-91.
20. Kaplan BS, Chesney RW, Drummond KN. Hemolytic uremic syndrome in families. N Engl J Med 1975;784:1090-3.
21. Karcz J, Uszycka-Karcz M, Gross R. Gastrointestinale Komplikationen bei Kindern mit hämolytisch-urämischem Syndrom. Z Kinderchir 1984;39:373-6.
22. Schindera F, Künzer W. Das hämolytisch-urämische Syndrom. Pädiatr Prax 1980;23:401-11.
23. Siegler RL. Spectrum of extrarenal involvement in postdiarrheal haemolytic-uremic syndrome. J Pediatr 1994;125:511-8.
24. Razzaq S. Hemolytic-uremic syndrome: an emerging health risk. AAFP 2006;74:1-5.
25. Rossi CE, Caroue FA, Del Greco F. Platelets and the hemolytic uremic syndrome. Ann Clin Lab Sci 1981;11:269-73.
26. Roth B, von Lilien T, Busch B etal. Deficiency of antithrombin-III in children with hemolytic-uremic syndrome. Pediatrics 1984;142:16-20.
27. Klein PJ, Vierbuchen M, Bulla M etal. Hämolytisch-urämisches Syndrom (HUS): Histochemischer Nachweis spezieller infektiös-toxischer Nierenveränderungen. In: Gessler U, Seybold D, eds. Glomerulonephritis. Stuttgart: Thieme Verlag, 1980;96-104.
28. Bambauer R, Jutzler GA, Jesberger HJ etal. Therapeutischer Plasma-Austausch beim hämolytisch-urämischen Syndrom. Dtsch Med Wschr 1988;113:1245-9.
29. Tarr PI, Gordon CA, Chandler WI. Shiga toxin-producing Escherichia coli and the haemolytic uraemic syndrome. Lancet 2005;365:1073-86.
30. Karch H, Tarr PI, Bielaszewska M. Enterohaemorrhagic Escherichia coli in humane medicine. Int J Med Microbiol 2005;295:405-18.
31. Delano BG. E. coli 0157: H7-associated diarrhea and the hemolytic syndrome. Dial Transplant 1996;25:205-9.
32. Siegler RL, Pysher TJ, Tesh VL etal. Response to single and divided doses of Shiga Toxin-1 in a primate model of hemolytic uremic syndrome. J Am Soc Nephrol 2001;12:1458-62.
33. Bielaszewska M, Köck R, Friedrich AW etal. Shiga toxin-mediated hemolytic uremic syndrome: time to change the diagnostic paradigm? PLoS ONE 2007;2:e1024.
34. Spaer JD, Rondeau E, Kaufer A etal. Proagulant and fibrinolytic activity of human glomeruli cultured cells. J Nephrol 1990;1:45-52.
35. Shaikh N, Tarr PI. Escherichia coli O157:H7 Shiga toxin-encoding bacteriophages: integrations, excisions, truncations, and evolutionary implications. J Bacteriol 2003;185:3596-605.
36. Bielaszewska M, Prager R, Köck R etal. Shiga toxin gene loss and transfer in vitro and in vivo during enterohemorrhagic Escherichia coli O26 infection in humans. Appl Envron Microbiol 2007;73:3144-50.
37. Wagner PL, Waldor MK. Bacteriophage control of bacterial virulence. Infect Immun 2002;70:3985-93.
38. Bielaszewska M, Friedrich AW, Aldick T etal. Shiga toxin activatable by intestinal murus in Escherischia coli isolated from human: predictor for a severe clinical outcome. Clin Infect Dis 2006;43:1160-7.
39. Brooks JT, Sowers EG, Wells JG etal. Non-O157 Shiga toxin-producing Escherichia coli infections in the United States, 1983-2002. J Infect Dis 2005;192:1422-9.
40. Mellmann A, Bielaszewska M, Zimmerhackl LB etal. Enterohaemorrhagic Escherichia coli in human infection in vivo evolution of a bacterial pathogen. Clin Infect Dis 2005;41:785-92.
41. Friedrich AW, Zhang W, Bielaszewska M etal. Prevalence, virulence profiles, and clinical significance of Shiga toxin-negative variants of enterohemorrhagic Escherichia coli O157 infection in humans. Clin Infect Dis 2007;45:39-45.
42. Ohali M, Shalev H, Schlesinger M etal. Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H. Pediatr Nephrol 1998;12:619-24.
43. Norris M, Rugenenti P, Perna A etal. Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. J Am Nephrol 1999;10:281-93.
44. Fremeaux-Bacchi V, Kemp EJ, Godship JA etal. The development of haemolytic uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts. J Med Genet 2005;42:852-6.
45. Koster F, Levin J, Walker L etal. Hemolytic-uremic syndrome after shigellosis: relation to endotoxemia and circulating immune complexes. N Engl J Med 1978;298:927-32.
46. Bohle A, Helmchen U, Grund KE etal. Malignant nephrosclerosis in patients with hemolytic uremic syndrome (Primary malignant nephrosclerosis). Curr Top Pathol 1977;65:81-113.
47. Proia AD, Harden EA, Silberman HR. Mitomycin-induced haemolytic-uremic syndrome. Arch Pathol Lab Med 1984;108:959-62.
48. Giroux L, Bettez P, Giroux L. Mitomycin-C nephrotoxicity: a clinicopathologic study of 17 cases. Am J Kidney Dis 1985;6:28-39.
49. Canpolat C, Pearson P, Jaffe N. Cisplatin-associated haemolytic uremic syndrome. Cancer 1994;74:3052-62.
50. Hofheinz RD, Nguyen XD, Buchheidt D etal. Two potential mechanisms of oxaliplatin-induced haemolytic anaemia in a single patient. Cancer Chemother Pharmacol 2004;53:276-7.
51. Chen V, Thrift K, Morel-Kopp MC etal. An immediate hemolytic reaction induced by repeated administration of oxaliplatin. Transfusion 2004;44:838-43.
52. Crocker J, Jones EL. Haemolytic-uremic syndrome complicating long-term mitomycin-C and 5-fluorouracil therapy for gastric carcinoma. J Clin Pathol 1983;36:24-9.
53. Cantrelli JE, Phillips TM, Schein PS. Carcinoma associated hemolytic-uremic syndrome: a complication of mitomycin-C chemotherapy. J Clin Oncol 1985;3:723-34.
54. Watson PR, Guthrie TH, Caruna RJ. Cisplatin-associated haemolytic-uremic syndrome, successful treatment with staphylococcal protein A column. Cancer 1989;64:1400-3.
55. Thurnher D, Kietzmayr J, Fomanek M etal. Chemotherapy-related haemolytic-uremic syndrome following treatment of a carcinoma of the nasopharynx. Oncology 2001;61:143-6.
56. Serk S, Riese H, Oettle H etal. Elevated reticulocyte count-a due to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report. Br J Cancer 1999;79:1519-21.
57. Lesesne JB, Rothschild N, Erikson B etal. Cancer-associated haemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989;7:781-9.
58. Desrame J, Broustet H, Darodes de Tailly P etal. Oxaliplatin-induced haemolytic anemia. Lancet 1999;354:1179-80.
59. Earle CC, Chen WY, Ryan DP etal. Oxaliplatin-induced Evan's syndrome. Br J Cancer 2001;84:441-1.
60. Sorbye H, Bruserud O, Dahl O. Oxaliplatin-induced hematological emergency with an immediate severe thrombocytopenia and hemolysis. Acta Oncol 2001;40:882-3.
61. Remuzzi G, Marchesi D, Mecca G etal. Haemolytic-uraemic syndrome: deficiency of plasma factor(s) regulating prostacyclin activity? Lancet 1978;II:871-2.
62. Levin M, Elkon KB, Nokes TJC etal. Inhibitor of prostacyclin production in sporadic haemolytic uraemic syndrome. Arch Dis Child 1983;58:703-6.
63. Webster J, Rees AJ, Lewis PJ etal. Prostacyclin deficiency in haemolytic-uraemic syndrome. Br Med J 1980;26:271-5.
64. Stuart MJ, Roger BS, Spitzer E etal. Prostanoids in hemolytic uremic syndrome. J Pediatr 1985;106:936-40.
65. Neild GH. Hämostase beim hämolytisch-urämischen Syndrom. Hämostaseologie 1984;4:123-6.
66. Siegler R, Oakes R. Hemolytic uremic syndrome, pathogenesis, treatment and outcome. Curr Opin Pediatr 2005;17:200-4.
67. Waldherr R. Pathomorphologie des hämolytisch-urämischen Syndroms. Hämostaseologie 1984;4:127-32.
68. Bergstein JM, Edson JR, Michael AF. Fibrinolytic treatment of the haemolytic-uraemic syndrome. Lancet 1972;II:448-52.
69. Monnens L, Kleynen F, van Munster P etal. Coagulation studies and streptokinase therapy in the haemolytic-uremic syndrome. Helv Paediatr Acta 1972;27:45-54.
70. Brain MC, Baker LRJ, Mc Bride JA etal. Treatment of patients with microangiopathic haemolytic anaemia with heparin. Br J Haematol 1968;15:603-21.
71. Liebermann E. Hemolytic uremic syndrome. J Pediatr 1972;80:1-6.
72. Bläker F, Altrooge H, Hellwege HH etal. Dialysebehandlung des schweren hämolytisch-urämischen Syndroms. Dtsch Med Wschr 1978;103:1229-32.
73. Kaplan BS, Thompson PD, Chadarevian JP. The haemolytic uremic syndrome. Pediatr Clin North Am 1976;23:761-77.
74. Misiani R, Appiani AC, Edefonti E etal. Haemolytic uremic syndrome: therapeutic effect of plasma infusion. Br Med J 1982;285:1304-6.
75. Korec S, Schein PS, Smith FP etal. Treatment of cancer-associated haemolytic uremic syndrome with staphylococcal protein A immunoperfusion. Clin Oncol 1986;4:210-5.
76. Gaddis TG, Guthrie TH, Drew MJ etal. Treatment of plasma refractory thrombotic thrombocytopenic purpura with protein A immunoabsorption. Am J Hematol 1997;55:55-8.
77. Snyder HW, Mittelmann A, Oral A etal. Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma. Cancer 1993;71:1882-92.
78. Kaplan AA. Therapeutic apheresis for cancer related uremic syndrome. Ther Apher 2001;4:201-6.
79. Dittrich E, Schmaldienst S, Derfler K. Plasmaaustausch und Immunadsorption. Wien Klin Wschr 2007;2:39-54.
80. Parmar MS. Hemolytic-uremic syndrome: treatment & Medication. eMedicine 2008;Dec 5.
81. Kaplan AA. Apheresis for renal disease. Ther Apher 2001;5:134-41.
82. Stegmayr BG, Almroth G, Berlin G etal. Plasma exchange or immunoadsorption in patients with rapidly progressive crescentic glomerulonephritis. A Swedish multi-center study. Int J Artif Organs 1999;22:81-5.
83. Bukowski RM, King JW, Hewlett JS. Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. Blood 1977;50:413-7.
84. Denneberg T, Freidberg M, Holmberg L etal. Combined plasmapheresis and hemodialysis for severe haemolytic uremic syndrome following campylobacter colitis. Acta Pedr Scan 1982;71:243-6.
85. Gillor A, Bulla M, Roth B etal. Plasma exchange as a therapeutic measure in haemolytic-uremic syndrome in children. Klin Wschr 1983;61:363-7.
86. Müller-Wiefel DE, Bulla M, Balzer E etal. Therapeutic trial hemolytic uremic syndrome (HUS) with membrane plasmaseparation (MPS). Blood Purif 1989;7:269.
87. Do AJT, Silverberg MA. Hemolytic uremic syndrome. Treatment and medication. eMedicine 2009;June 17.
88. Szczepiorkowski ZM, Bandarenko N, Kim C. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2007;22:106-75.
89. Bosch T, Braun N, Fassbinder W etal. Apherese-Standard der Deutschen Arbeitsgemeinschaft für Klinische Nephrologie e.V. Mitt Deutschen Arbeitsgemeinschaft Klinische Nephrologie 2002;XXXI:103-38.
90. Szczepiorkowski ZM, Shaz BH, Bandarenko N etal. The new approach to assignment of ASFA categories-introduction to the fourth special issue: clinical applications of therapeutic apheresis. J Clin Apher 2007;22:96-105.
91. Hanna J, Sheth KJ, Gill J etal. Effect of fresh frozen plasma (FFP) infusions on the outcome of haemolytic uremic syndrome (HUS). Kidney Int 1987;31:200-5.
92. Rizzoni G, Pavanello L, Claris-Appiani A etal. Treatment of children with hemolytic uraemic syndrome (HUS) with plasma: a multicenter controlled trial. Helv Paediatr Acta 1986;41:114-7.
93. O'Reagan S, Blaus N, Russo P etal. Hemolytic uremic syndrome: glomerular filtration rate, 6 to 11years later measured by 99m Tc DTPA plasma slope clearance. Clin Nephrol 1989;32:217-21.
94. Arenson EB, August CS. Preliminary report: treatment of the hemolytic uremic syndrome with aspirin and dipyridamole. J Pediatr 1975;86:957-60.
95. O'Regan S, Chesney RW, Mongeau JG etal. Aspirin and dipyridamole therapy in the hemolytic-uremic syndrome. J Pediatr 1980;97:473-8.
96. Bambauer R, Jutzler GA, Mauch H etal. Ein vereinfachtes Plasmapherese-Behandlungsverfahren. Technik und erste klinische Ergebnisse. Nieren- u Hochdruckkrankh 1981;10:126-34.
97. Cattran DC. Adult hemolytic-uremic syndrome: successful treatment with plasmapheresis. Am J Kidney Dis 1984;3:275-9.
98. Gillor A, Roth R, Bulla M etal. Plasmapherese bei der Behandlung von Kindern mit hämolytisch-urämischen Syndrom. Nieren- Hochdruckkrankh 1986;15:118-25.
99. Bulla M. Die hämolytisch-urämischen Syndrome (HUS). Nieren- Hochdruckkrankh 1988;17:428-34.
100. Ciechanska E, Segal L, Wong H etal. Plasma exchange using a continuous venovenous hemofiltration maschine in children. Blood Purif 2005;23:440-5.
101. Davin JC, Buter N, Groothoff J etal. Prophylactic plasma exchange in CD46-associated atypical haemolytic uremic syndrome. Pediatr Nephrol 2009;24:1757-60.
102. Talbert RL, Wong YY, Duncan DB. Propranonol plasma concentration and plasmapheresis. Drug Intell Clin Pharm 1981;15:993-6.
103. Sweny P, Winnig A, Gross MLP etal. Plasmapheresis in the haemolytic-uraemic syndrome in childhood. Br Med J 1981;282:2137.
104. Bergada E, Torras A, Puig L etal. Plasmapheresis-dependent recovery from recurrent hemolytic-uremic syndrome. Int J Artif Organs 1983;6:79-83.
105. Kalmin ND, Himot ED. Plasmapheresis in a child with the haemolytic-uraemic syndrome. Transfusion 1983;23:139-42.
106. Lyman NW, Michaelson R, Viscuso RL etal. Miromycin-induced hemolytic-uremic syndrome. Successful treatment with corticosteroids and intensive plasma exchange. Arch Intern Med 1983;143:1617-18.
107. Vogel W, Huber C. Erfolgreiche Behandlung eines Falles von postpartalem hämolytisch-urämischen Syndrom mittels Plasmapherese. Wien Klin Wschr 1983;95:175-7.
108. Borghardt EJ, Kirchertz EJ, Marten I etal. Protein A-immunoadsorption in chemotherapy associated hemolytic-uremic syndrome. Transfus Sci 1997;19:5-7.
109. Shemin D, Dworkin LD. Clinical outcome in three patients with postpartum haemolytic uremic syndrome treated with frequent plasma exchange. Ther Apher 1998;2:43-6.
110. Michael M, Elliot EJ, Craig JC etal. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kid Dis 2009;53:259-72.